Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Acquire 492,611 Treasury Shares Worth Approx. KRW 100B on Market for Stock Price Stabilization and Boosting Shareholder Value

Posted on April 22, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Acquire 492,611 Treasury Shares Worth Approx. KRW 100B on Market for Stock Price Stabilization and Boosting Shareholder Value

Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-04-22

Disclosure Type: Decision on Acquisition of Treasury Shares

💡 3-Second Summary

Celltrion has officially decided to acquire 492,611 shares of its common stock, valued at approximately KRW 100B, through open-market purchases on the KRX. The scheduled buyback period is set to run from April 23, 2026, through July 22, 2026.

📊 1. [Key Disclosure Details & Major Figures Summary]

  • Purpose of Acquisition: Price stabilization and enhancement of shareholder value
  • Type and Number of Shares to be Acquired: 492,611 Common Shares (No other share classes involved)
  • Estimated Acquisition Value: KRW 100,000,033,000
    • Note: This projected amount is calculated based on the closing stock price of KRW 203,000 on the day prior to the board resolution (April 21, 2026). The actual total value may fluctuate based on future market price movements.
  • Expected Acquisition Period: April 23, 2026 ~ July 22, 2026
  • Acquisition Method & Entrusted Broker: On-market purchase via the domestic stock exchange / NH Investment & Securities Co., Ltd.
  • Daily Purchase Order Limit: 118,671 Common Shares
    • Basis of calculation: Apportioned at 25% of the average daily trading volume over the 1-month period prior to the board resolution date.
  • Prior Treasury Share Holdings: 3,226,478 Common Shares held under “other acquisitions” as of the reporting date (April 22, 2026), representing 1.5% of total outstanding shares.
    • Expected retention period: 6 months or longer from the final acquisition date.
  • Financial Limit Availability: Based on the separate financial statements as of December 31, 2025, the legal limit for treasury share acquisitions under the Commercial Act is KRW 4,693,200,652,848. The proposed KRW 100B allocation remains strictly within this regulatory threshold.

📈 2. [Expert Perspective: What This Means for Investors]

  • Execution of Shareholder Returns via Buyback Plan: This filing provides objective verification of Celltrion’s corporate commitment to allocate internal capital toward buying back its own stock. Investors can utilize the explicit parameters—specifically the targeted buyback volume of 492,611 shares and the 3-month operational window—as definitive baseline metrics.
  • Ample Legal Headroom for Share Repurchases: According to the financial breakdown disclosed in the filing, the company’s dividendable profit headroom for buybacks stands at approximately KRW 4.69T. This factual parameter indicates that the current KRW 100B purchase plan is structurally robust and fully supported by corporate retained earnings under commercial regulations.
  • Potential Variance in Final Metrics: Because the total estimated acquisition value relies on a fixed historical closing price (KRW 203,000), daily variations in execution prices during the operational period will naturally affect the numbers. Market participants should note that the absolute share count or total expenditure finalized at completion may deviate from these initial parameters, requiring reconciliation against future completion filings.

📝 Editor’s Comment (by K-STOCK Editor)

This corporate filing sets forth the quantitative framework for Celltrion’s open-market treasury share buyback of 492,611 shares aimed at market stabilization. The document presents structural rules, including the precise duration (April 23 to July 22) and the daily transaction limit (118,671 shares). Rather than formulating speculative assessments regarding downstream market price effects or financial outcomes, investors are advised to focus strictly on these documented rules and monitor the systematic execution of the repurchase program through its designated broker over the coming months.

📢 Disclaimer & Sources

Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Jusung Engineering (036930) Designated as Investment Warning Stock Effective April 23; Margin Trading Halted and 100% Cash Deposit Enforced
Next Post: [Disclosure] SK square (402340) Subsidiary SK hynix Prepares $11.2M Treasury Share Disposal for Executive Compensation… Any Overhang Risks?

Related Posts

[Disclosure] Celltrion (068270) Sets December 31, 2025 as Record Date to Determine Shareholders Eligible for Year-End Dividend Disclosures
[Disclosure] Alteogen (196170) Receives Advance Notice of Unfaithful Disclosure Corporation Designation Following Two Cases of Mergers and Acquisition Cancellations Disclosures
[Disclosure] Alteogen (196170) to Host Domestic IR in Yeouido, Signaling Major Updates on Bio Platform & Pipelines Disclosures
[Disclosure] SK Hynix (000660) Subsidiary ‘Solidigm Inc.’ Decides on 14.7 Trillion KRW Capital Increase for Business Acquisition Semiconductors
[Disclosure] Celltrion (068270) Decides to Dispose of 11,379 Treasury Shares Worth KRW 1.65B for Stock Option Settlements Disclosures
[Disclosure] Alteogen (196170) Transferred from Technology Growth Business Division to Blue-Chip Business Division Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme